ventures
Developing highly selective cancer therapies using proprietary “twin antigen fingerprint” technology to enable precise Bi-Cygni treatments that target the cancer, not the patient.
Developing lipid nanoparticle-based mRNA therapies to regenerate inner ear cells and transform the treatment of hearing loss.
University of Leeds spinout developing a next-generation small molecule to outperform tranexamic acid and transform bleeding management across clinical settings.
Developing the CASPAROV platform to uncover novel drug targets and biomarkers by analysing tumour diversity driven by chromosomal instability in complex cancers.
Developing a novel gene modulation technology with broad applications, offering new therapeutic possibilities for patients with rare diseases.
Developing small-molecule therapeutics targeting novel mechanisms to prevent or delay age-related diseases and promote healthy longevity.
University of Oxford spinout leveraging AI-driven drug discovery to develop novel therapeutics for oncology and high-threat pathogens, supported by validated in vivo data.